Humanigen

A recent article from WLWT5 discusses the need for treatments as the delta variant increases hospitalization rates. was mentioned as a new and promising COVID-19 treatment. As hospitalizations from COVID-19 continue to rise highlights the need for additional treatments.

is intended for patients who are newly hospitalized with pneumonia, but not yet on mechanical ventilation; however, it is not yet authorized, or approved, in any country.



Read more:

https://www.wlwt.com/article/more-covid-19-patients-survive-hospitalizations-with-more-promising-treatments-ahead/37435624 #

More COVID-19 patients survive hospitalizations with more promising treatments ahead Even as the delta variant drives more COVID-19 patients to hospitals, treatments are getting more effective at saving them.

A recent article by the Twin Cities Pioneer Press covered the increasing hospitalizations in Minnesota. The number of Minnesotans hospitalized with COVID-19 has more than doubled during the month of August, contributing to a tightening supply of available beds across the state.

The latest surge in cases is driven by the more contagious delta variant, which health officials suspect can also cause more severe illness. Serious cases are most common in older residents, but since delta became the main source of infections, severe cases have trended younger, health officials say.

This steep increase in hospitalizations have also left Minnesota healthcare workers stressed and tired. It’s led to an exodus of care providers and nearly every part of Minnesota has been affected. Some providers have two to three times the open jobs they typically had before the pandemic. As hospitalization rates continue to increase there remains a continued need for effective therapeutics.



Read more:

Rising number of COVID-19 patients increases stress on Minnesota hospitals The number of Minnesotans hospitalized with COVID-19 has more than doubled during the month of August, contributing to a growing scarcity of hospital beds across the state.

According to Fox News cases have nearly doubled in the past two weeks. According to Johns Hopkins University, The US recorded an average of about 509 deaths a day for the week ending on August 8th, to nearly a 97% increase to about 1000 deaths for the week ending on august 22nd.

All three COVID-19 vaccines available in the United States are considered very effective at preventing serious illness leading to hospitalization or death. However, so-called breakthrough infections where fully vaccinated individuals test positive for COVID-19 could be rising, according to a New York Times report citing preliminary data from six states.

’s treatment drug is intended for patients who are newly hospitalized with pneumonia, but not yet on mechanical ventilation; however, it is not yet authorized, or approved, in any country.


Read more:

Daily U.S. COVID-19 deaths nearly double in 2 weeks The rolling seven-day average of daily coronavirus-related deaths in the United States has nearly doubled in the past two weeks.

CEO, Cameron Durrant, MD, MBA, will be a guest on The Inclusive Voice Radio Talk Show with host Pam McElvane. Tune in on Saturday at 7:00 am CST / 8:00 am EST as Cameron Durrant and Brian D. Smedley, PhD Chief of Psychology American Psychological Association, discuss the vaccination dilemma and the need for treatments.

’s treatment drug lenzilumab is intended for patients who are newly hospitalized with pneumonia, but not yet on mechanical ventilation; however, it is not yet authorized, or approved, in any country.



Listen here tomorrow:

The Inclusive Voice 8.21.21 Where FACTS MATTER! We are the progressive itch you needed to scratch! Listen to all of our shows to find out what is going on in today's politics. Follow our socials on our LINKS tab!

The demand for treatments for was mentioned in a recent article on Healio. As the delta variant continues to sweep across the nation, the demand for treatments has outpaced the global supply.

As hospitalizations are unexpectedly increasing across the country, it has led to an unprecedented demand for treatments that the global supply is not able to keep up with. Due to this sudden high demand of tocilizumab it is anticipated that there will be periods of stockout in the weeks and months ahead.

’s treatment drug lenzilumab is intended for patients who are newly hospitalized with pneumonia, but not yet on mechanical ventilation; however, it is not yet authorized, or approved, in any country.



Read more:

Global tocilizumab shortage intensifies after demand spikes to treat delta variant Demand for tocilizumab IV has outpaced the global supply, exacerbated by increased demand following the drug’s emergency use authorization for COVID-19 and the surge in delta variant cases, the American College of Rheumatology reported. Although the ACR noted that it is actively involved with....